CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Mark Montebello

OPENALEX: A5037358261↗ORCID: 0000-0002-1776-3974↗

Affiliations

Organizations

Albion Centreauthorship · AU Hunter New England Local Health Districtauthorship · AU Mental Health Commissionauthorship · AU New South Wales Department of Healthauthorship · AU Northern Sydney Local Health Districtauthorship · AU South Eastern Sydney Local Health Districtauthorship · AU Sydney Local Health Districtauthorship · AU The University of Sydneyauthorship · AU UNSW Sydneyauthorship · AU

Public evidence

4 connected articles

A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.2024 · Europe PMC Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.2022 · Europe PMC The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.2021 · Europe PMC Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.2018 · Europe PMC

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Mark Montebello - Medical Cannabis Research Engine